Literature DB >> 2861667

Limitations of 131I-MIBG scintigraphy in locating pheochromocytomas.

I R Gough, N W Thompson, B Shapiro, J C Sisson.   

Abstract

131I-metaiodobenzylguanidine (131I-MIBG) scintigraphy for the location of pheochromocytomas has proved to be a major advance in patient management. In combination with computerized tomographic scanning, nearly all pheochromocytomas can be located before surgery and invasive investigations are now indicated only in exceptional cases. However, there are still lessons to be learned concerning the optimal administration and interpretation of 131I-MIBG scintigraphy. With careful attention to detail and an awareness of isotope distribution, false positive studies should be extremely rare. While the incidence of false negative studies is uncommon, these certainly occur. A patient with sporadic bilateral adrenal medullary hyperplasia, bilateral pheochromocytomas, and additional benign pheochromocytomas arising in paraganglia tissue anterior to the abdominal aorta is presented. The right adrenal pheochromocytoma was not identified on 131I-MIBG imaging. We conclude that even with current locating techniques, the traditional surgical approach to pheochromocytoma should not be abandoned. This involves transabdominal exploration of both adrenal glands and careful examination of all possible sites of extra-adrenal pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861667

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  2 in total

1.  Pheochromocytoma. Lateral versus anterior operative approach.

Authors:  G L Irvin; L M Fishman; J A Sher; L K Yeung; H Irani
Journal:  Ann Surg       Date:  1989-06       Impact factor: 12.969

2.  High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991.

Authors:  C Proye; M Vix; A Goropoulos; P Kerlo; M Lecomte-Houcke
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.